Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652970 | 0.74 | PKM (0.53) | PKMHSD17B10ALDH1A1KCNA3LMNA | |
| SCHEMBL14374689 | 0.73 | PKM (0.57) | PKMHSD17B10NPC1TP53RAB9A | |
| SCHEMBL13240433 | 0.73 | PKM (0.49) | PKMHSD17B10NPC1TP53RAB9A | |
| SCHEMBL15869563 | 0.71 | LMNA (0.63) | HSD17B10NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL30896547 | 0.70 | HSD17B10 (0.68) | PKMHSD17B10NPC1TP53RAB9A | |
| SCHEMBL299421 | 0.69 | ALDH1A1 (0.50) | PKMHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL9292620 | 0.69 | ALDH1A1 (0.50) | PKMHSD17B10ALDH1A1KCNA3LMNA | |
| Saccharin SCHEMBL7361433 | 0.69 | ALDH1A1 (0.53) | PKMHSD17B10ALDH1A1KCNA3LMNA | |
| SCHEMBL299692 | 0.69 | ALDH1A1 (0.50) | PKMHSD17B10ALDH1A1KCNA3LMNA | |
| SCHEMBL29695488 | 0.69 | ALDH1A1 (0.50) | PKMHSD17B10ALDH1A1KCNA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380598-B1 | ENZYME STABILIZERS | HENKEL AG & CO KGAA (DE) | 2019-08-21 | — | — | EP | claimed |
| US-20180340138-A1 | ENZYME STABILIZERS | HENKEL AG & CO. KGAA (DE) | 2018-11-29 | — | — | US | claimed |
| EP-3380598-A1 | ENZYME STABILIZERS | Henkel AG & Co. KGaA (DE) | 2018-10-03 | — | — | EP | claimed |
| CN-116554119-A | Enantioselective reduction (hetero) arylation method of cobalt-catalyzed cyclic N-sulfonyl imine and application | 上海毕得医药科技股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-3380598-B1 | ENZYME STABILIZERS | HENKEL AG & CO KGAA (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180340138-A1 | ENZYME STABILIZERS | HENKEL AG & CO. KGAA (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3380598-A1 | ENZYME STABILIZERS | Henkel AG & Co. KGaA (DE) | 2018-10-03 | — | — | EP | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-7465745-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-7326719-B2 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312211-B2 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-12-25 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-20040180886-A1 | Cathepsin S inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-1991016316-A1 | PROCESS FOR PREPARING ISOXAZOLINES | BP CHEMICALS LIMITED (GB) | 1991-10-31 | — | — | WO | disclosed |
| EP-0453189-A1 | Process for preparing isoxazolines | von Oppolzer, Wolfgang Wilhelm R.E.J. (CH) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | PKM 2335/4885HSD17B10 212/4885NPC1 27/4885 |
| US-20040180886-A1 | Cathepsin S inhibitors | CTSS, CTSB, CTSZ | PKM 3345/4885HSD17B10 3442/4885NPC1 263/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PKM 987/4885HSD17B10 465/4885NPC1 177/4885 |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PKM 2294/4885HSD17B10 1174/4885NPC1 1269/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PKM 987/4885HSD17B10 465/4885NPC1 177/4885 |
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | KRAS, NRAS, HRAS | PKM 3124/4885HSD17B10 4764/4885NPC1 3960/4885 |
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PKM 987/4885HSD17B10 465/4885NPC1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.